Rubedo doses first patient in trial targeting senescent skin cells

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

RLS-1496 enters Phase 1 aiming to modulate GPX4 and reduce cellular senescence – could precision therapies for skin aging be on the horizon?

Rubedo Life Sciences has announced that the first participant has been dosed in a Phase 1 clinical trial evaluating RLS-1496, its lead senescence-targeting drug candidate. The study, which is taking place in the Netherlands focuses on healthy adults with various skin conditions, including mild to moderate plaque psoriasis – but the company’s stated goal reaches far beyond dermatological disease. RLS-1496 is the first known GPX4 modulator to enter human trials, and Rubedo’s wider aim is to validate a platform that identifies and targets pathologic senescent cells implicated in tissue dysfunction and chronic inflammation – factors increasingly central to our understanding of skin aging and the broader biology of aging itself.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2388

Rubedo Life Sciences

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Rubedo Life Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule therapeutics that selectively target pathologic senescent cells—dysfunctional aging cells that accumulate with age and drive chronic disease. The company employs its proprietary ALEMBIC platform, an AI-driven drug discovery system, to identify and modulate specific cellular targets across multiple therapeutic areas including dermatology, pulmonary fibrosis, neurodegenerative disease, and oncology. By addressing the fundamental mechanisms of cellular aging rather than disease symptoms alone, Rubedo aims to extend human healthspan and restore biological youth at the cellular level.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Beauty giant and supplement startup both chase skin aging

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE